A Hyderabad-based vaccine company today announced that it received regulatory approval to launch a Phase III clinical trial for a COVID-19 vaccine candidate.
Biological E. Limited (BE) confirmed on April 23, 2021, its subunit COVID-19 vaccine candidate includes an antigen developed by Texas Children’s Hospital Center for Vaccine Development and in-licensed from Baylor College of Medicine’s integrated commercialization team along with Dynavax Technologies Corporation’s advanced adjuvant CpG 1018TM.
Read More
